A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.
An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
